1785 Jianghai Road,building No.1
58 articles with Ascletis, Inc.
AstraZeneca will showcase its early oncology portfolio at the American Association for Cancer Research set to begin on April 8.
Ascletis Announces Further Expansion of Ritonavir Oral Tablet Production Capacity to 530 Million Tablets Per Year
Ascletis Pharma Inc. announces that it has further expanded its ritonavir oral tablet production capacity to approximately 530 million tablets per year, to meet the potential escalation in the domestic and global demands.
Shanghai Public Health Clinical Center Initiated Functional Cure Study of Anti-PD-L1 Antibody ASC22 (Envafolimab) in Combination With Chidamide in HIV-Infected Patients
Ascletis Pharma Inc. announces that Shanghai Public Health Clinical Center initiated functional cure study of anti-PD-L1 antibody ASC22 in combination with Chidamide in patients infected by human immunodeficiency virus with antiviral suppression.
Ascletis Announces Submission of Marketing Authorization Applications for Ritonavir in Multiple European Countries
Ascletis Pharma Inc. announces that it has submitted marketing authorization applications for ritonavir in Germany, France, Ireland and United Kingdom through its agent in Europe.
Ascletis Announces U.S. IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors
Ascletis Pharma Inc. announces the approval of the Investigational New Drug application by U.S. Food and Drug Administration for in-house developed oral PD-L1 small molecule inhibitor, ASC61, for the treatment of advanced solid tumors.
Ascletis Announces First Patient Dosed in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma
Ascletis Pharma Inc. announces the dosing of the first patient in the Phase III registration clinical trial of ASC40 combined with bevacizumab for treatment of recurrent glioblastoma.
Ascletis Announces Signing of Ritonavir Tablet Purchase Agreement with Phokam Pharmaceutical Import-Export Co., Ltd of Laos
Ascletis Pharma Inc. announces signing of the ritonavir tablet purchase agreement between Phokam Pharmaceutical Import-Export Co., Ltd of Laos and Ascletis Pharmaceuticals Co., Ltd., a wholly-owned subsidiary of Ascletis Pharma Inc.
Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of FASN Inhibitor ASC40 for Treatment of Moderate to Severe Acne
Ascletis Pharma Inc. announces the dosing of the first patient in the Phase II clinical trial of ASC40 for moderate to severe acne.
Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of ASC42, An In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication
Ascletis Pharma Inc. announces the dosing of the first patient in the Phase II clinical trial of ASC42 for chronic hepatitis B indication.
Ascletis Announces U.S. IND Filing for In-House Developed Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors
Ascletis Pharma Inc. announces the filing of the U.S. Investigational New Drug application for in-house developed oral PD-L1 small molecule inhibitor, ASC61, for the treatment of advanced solid tumors.
Low-income countries still struggle to get first jabs into arms. Researchers and pharma companies continue to push for low-cost vaccines and drugs worldwide.
Ascletis Announces Inclusion in New Catalogue of China National Reimbursement Drug List (NRDL) of ASCLEVIR®/ GANOVO® Regimen, an All-oral Direct Anti-HCV Therapy
Ascletis Pharma Inc. announces that its all-oral direct anti-hepatitis C virus ASCLEVIR® / GANOVO® regimen has been included in the Medicine Catalog for National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance .
Ascletis Announces Dosing of the First Cohort of Healthy Subjects in the FXR Agonist ASC42 Bridging Study for Chronic Hepatitis B Indication in China
--This bridging study to select doses for the Phase II trial in China in patients with chronic hepatitis B (CHB) --ASC42 clinical trials are being conducted in the U.S. and China for non-alcoholic steatohepatitis (NASH) and CHB.
Clinical Trial Application of ASC40 Combined with Bevacizumab to Treat Patients with Recurrent Glioblastoma Accepted by China NMPA
Ascletis Pharma Inc. (HKEX code: 1672) today announces that following the consultation with China National Medical Products Administration (NMPA), the clinical trial application of ASC40 combined with bevacizumab to treat patients with recurrent glioblastoma (rGBM) has been accepted for review by China NMPA.
Change in Use of Proceeds From the Global Offering for Expansion of R&D Portfolio into Hepatitis B Clinical Cure and NASH
Ascletis Pharma Inc. announces that the board of directors of the Company resolved to change the use of the remaining Net Proceeds from the Global Offering.
Ascletis Pharma Inc. (HKEX code: 1672) announces today that it completed bridging study of ASC18, first one-pill, once-a-day fixed dose combination (FDC) as the complete hepatitis C treatment developed by a Chinese biotech. ASC18 FDC consists of 200 mg Ravidasvir (RDV) and 400 mg Sofosbuvir (SOF). This phase I brid
First HBV Patient Dosed in Phase IIa Clinical Trial of ASC22, a Subcutaneously Administered PD-L1 Antibody
Ascletis Pharma Inc. announces dosing of the first HBV patient in Phase IIa clinical trial of ASC22, which is a first-in-class, subcutaneously administered PD-L1 antibody.
Ascletis Pharma Inc. announces that a single-dose, pharmacokinetic bridging study of non-alcoholic steatohepatitis drug candidate ASC40 in 34 Chinese subjects has been completed and data indicates that key pharmacokinetic parameters are consistent between subjects in China and in the United States.
Ascletis Pharma Inc. (HKEX code: 1672) announces today that it received IND approval from China's National Medical Products Administration (NMPA) for its in-house developed Category 1 Drug ASC41 to conduct clinical trials for Non-alcoholic Steatohepatitis (NASH) indication. Ascletis has two additional drug
Ascletis Pharma Inc. (HKEX code: 1672) announces today that it received IND approval from National Medical Products Administration (NMPA) for its human immunodeficiency virus (HIV) protease inhibitor ASC09F (ASC09/Ritonavir Fixed-Dose Combination). ASC09 has an unprecedented high genetic barrier to resistance and